c-LEcta, a leading biotechnology company in the fields of enzyme engineering and bioprocess development, has entered into an agreement with the Kerry Group for the group to acquire a majority stake. Kerry is a leading global supplier of flavors and nutrients to the food, beverage and pharmaceutical industries. The strategically compelling combination will strengthen Kerry’s ability to innovate in the areas of enzyme engineering, fermentation and bioprocess development while enabling cLEcta to realize its long-term growth potential.

We are very excited to become a member of the Kerry Group. Their global presence in the food and pharmaceutical sectors gives us access to additional markets. At the same time, their expertise in the field of ingredients technologies and applications is a perfect fit for us to better exploit our growth potential in the future. We will continue to work with our existing industrial partners and of course also manufacture and sell our products for our valued customers,” explains Dr. Marc Struhalla, Founder and CEO of c-LEcta.

“We would like to thank our previous investors for the good cooperation over the past few years. Without their contribution, such a development would not have been possible. Together we have achieved a lot and we are grateful for their support,” adds Thomas Pfaadt, CFO of c-LEcta.

“The food and pharmaceutical industry is on the threshold of a new wave of innovation,” comments Dr. Albert McQuaid, Kerry’s Chief Science and Technology Officer signed the agreement. “New developments in biotechnology, synthetic biology and precision fermentation are radically transforming these sectors. c-LEcta is at the forefront of these new technologies, which include fermentation-based products such as breakthrough new enzymes. The strategically compelling combination will strengthen our innovation capabilities in the areas of enzyme engineering, fermentation and bioprocess development. At the same time, our broad market presence in the food and pharmaceutical markets, combined with our in-depth know-how in the application of enzymes and the development of ingredient solutions, will activate and drive the growth potential of c-LEcta’s strong portfolio and technological capabilities – and while helping us create tastier, more sustainable and healthier products.”

c-LEcta is a leading biotechnology company based in Leipzig, Germany. It has established itself as a leading provider of high-quality biotechnological products for regulated markets, either as an in-house development or in close cooperation with industry. The innovative ability of c-LEcta ensures cost-efficient and sustainable production processes and thus creates growth opportunities in existing and new markets.

Kerry is a global leader in flavors and nutrients for the food, beverage and pharmaceutical industries, reaching more than a billion consumers worldwide with its broad portfolio of ingredients. Together with its customers, Kerry develops innovative products with a convincing taste, improved nutritional value and higher functionality, which at the same time make a contribution to environmental protection. Kerry’s leadership in consumer research, its global RD&A team of more than 1.100 food scientists, and its extensive, global footprint enable Kerry to solve its customers’ complex challenges with differentiated solutions. Kerry strives to be a valued partner to its customers and to promote sustainable eating. Visit kerrygroup.com for more information.

• www.biocity-campus.com

Source: Press release c-LEcta from November 15.02.2022th, XNUMX